Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Richard Stock on Brachytherapy for Prostate Cancer

March 14th 2015

Richard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.

Dr. Charles Ryan on Abiraterone in mCRPC

March 9th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the effects he has seen abiraterone have in patients with metastatic castration-resistant prostate cancer (mCRPC).

Henricks Applies NASA Concepts to Medicine at Prostate Congress

March 6th 2015

Former NASA astronaut Tom Henricks will show how team dynamics and organizational culture affect outcomes using dramatic real-life video shot inside of a NASA space shuttle cockpit during launch and landing, as well as scenes of working in space, during a keynote address at the 8th Annual Interdisciplinary Prostate Cancer Congress (IPCC): and Other Genitourinary Malignancies.

BMS, Bavarian Nordic Forge Immunotherapy Collaboration

March 5th 2015

A nearly $1 billion windfall licensing agreement involving the immunotherapy PROSTVAC has the company Bavarian Nordic looking toward a long-term manufacturing and distribution arrangement with Bristol-Myers Squibb.

Antonarakis Discusses AR-V7 and Response to Taxanes in mCRPC

March 4th 2015

Emmanuel S. Antonarakis, MBBCh, discusses research examining AR-V7 as a biomarker for chemotherapy efficacy in advanced prostate cancer.

Dr. Scholz on Using Abiraterone in mCRPC

March 4th 2015

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the final analysis of the COU-AA-302 study, which compared abiraterone acetate to prednisone alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

March 2nd 2015

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

Dr. Ryan on the Long Term Safety of Abiraterone Use

February 27th 2015

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27th 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

February 27th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer

February 27th 2015

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

Abiraterone OS Benefit Prolonged After Crossover Adjustment in mCRPC

February 27th 2015

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

No Survival Benefit From Adding Docetaxel to ADT in Hormone-Sensitive Prostate Cancer

February 27th 2015

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

Immunointensification May Favorably Alter Survival in mCRPC

February 27th 2015

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

Analysis Shows Increase in Higher-Risk Prostate Cancers

February 23rd 2015

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer

February 23rd 2015

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

Men with Testicular Cancer More Likely to Develop Prostate Cancer

February 23rd 2015

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

AR-V7 Not Predictive of Chemo Outcomes in mCRPC, But May Still Have Prognostic Value

February 23rd 2015

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations

February 18th 2015

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

ASCO Supports ACS Guidelines for Prostate Cancer Survivor Care

February 15th 2015

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.